Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-2334
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Pharmacokinetic study of two different rifabutin doses co-administered with lopinavir/ritonavir in African HIV and tuberculosis co-infected adult patients ; volume:20 ; number:1 ; day:26 ; month:6 ; year:2020 ; pages:1-10 ; date:12.2020
BMC infectious diseases ; 20, Heft 1 (26.6.2020), 1-10, 12.2020
- Creator
-
Kouanda, Seni
Ouedraogo, Henri Gautier
Cisse, Kadari
Compaoré, Tegwinde Rebeca
Sulis, Giorgia
Diagbouga, Serge
Roggi, Alberto
Tarnagda, Grissoum
Villani, Paola
Sangare, Lassana
Simporé, Jacques
Regazzi, Mario
Matteelli, Alberto
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1186/s12879-020-05169-2
- URN
-
urn:nbn:de:101:1-2020082719441530159546
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
19.04.20242024, 8:05 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Kouanda, Seni
- Ouedraogo, Henri Gautier
- Cisse, Kadari
- Compaoré, Tegwinde Rebeca
- Sulis, Giorgia
- Diagbouga, Serge
- Roggi, Alberto
- Tarnagda, Grissoum
- Villani, Paola
- Sangare, Lassana
- Simporé, Jacques
- Regazzi, Mario
- Matteelli, Alberto
- SpringerLink (Online service)
Other Objects (12)
Hepatic tolerability of fosamprenavir/ritonavir (FPV/RTV) in HIV/hepatitis C co-infected subjects with severe hepatic fibrosis
Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies
Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s
Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers
Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults
Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances
Managing antiretrovirals in co-infected patients in 2012
To be or not to be co-infected
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
Hepatic tolerability of fosamprenavir/ritonavir (FPV/RTV) in HIV/hepatitis C co-infected subjects with severe hepatic fibrosis
Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies
Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s
Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers
Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults
Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances
Managing antiretrovirals in co-infected patients in 2012
To be or not to be co-infected
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis
Population pharmacokinetic modelling of once-daily ritonavir-boosted darunavir in HIV-infected patients
Hepatic tolerability of fosamprenavir/ritonavir (FPV/RTV) in HIV/hepatitis C co-infected subjects with severe hepatic fibrosis
Development of a population pharmacokinetic/pharmacodynamic model for various oral paclitaxel formulations co-administered with ritonavir and thrombospondin-1 based on data from early phase clinical studies
Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s
Increased Exposure of Tacrolimus by Co-administered Mycophenolate Mofetil: Population Pharmacokinetic Analysis in Healthy Volunteers
Effects of CYP2B6 G516T polymorphisms on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults
Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
Physiologically based pharmacokinetic modeling of intravenously administered nanoformulated substances
Managing antiretrovirals in co-infected patients in 2012
To be or not to be co-infected
German cohort of HCV mono-infected and HCV/HIV co-infected patients reveals relative under-treatment of co-infected patients
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis